Toxoplasma Gondii: Chemotherapy
Infection with Toxoplasma gondii is widespread and has been observed in man and in almost all warm-blooded animals. Most immunologically normal adults acutely infected with T. gondii present only self-limited symptoms and signs. This is in great contrast with the morbidity and mortality that is observed in children with congenital and acquired toxoplasmosis, and in immunocompromised patients, notably those affected by the acquired immune deficiency syndrome (AIDS). Prompt antimicrobial therapy is given to patients with the aim of inhibiting the replication of the parasite and to prevent or to reduce the tissue damage resulting from parasitic intracellular multiplication. This therapy, nevertheless, is inactive against the non-multiplying (extracellular) or metabolically inactive (cyst) form of the parasite. Therapy of toxoplasmosis is further complicated by the possibility of harmful effects of the drugs on the fetus during therapy of pregnant women infected for the first time with T. gondii. The high frequency of side effects observed in AIDS patients treated for toxoplasmic encephalitis may lead to withdrawal of therapy and this enhances the possibilities of recurrent disease. All these considerations, therefore, point out the need for safer alternatives in the therapy of toxoplasmosis.
KeywordsAcquire Immune Deficiency Syndrome Antimicrob Agent Toxoplasma Gondii Congenital Toxoplasmosis Acquire Immune Deficiency Syndrome Patient
Unable to display preview. Download preview PDF.
- Chang HR, Pechere JCF (1987) Effect of roxithromycin on acute toxoplasmosis in mice. 31: 1147–1149.Google Scholar
- Chang HR, Pechere JC (1988a) In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii. Antimicrob Agents Chemother 32:524–529.Google Scholar
- Chang HR, Jefford CW, Pechere JC (1989) In vitro effects of three new 1,2,4-trioxanes (pentatroxane, thiahexatroxane, and hexatroxanone) on Toxoplasma gondii. Antimierob Agents Chemother 33: 1748–1752.Google Scholar
- Chang HR, Comte R, Pechere JC (1990) In vitro and in vivo effects of doxycycline on Toxoplasma gondii. Antimierob Agents Chemother 34:775–780.Google Scholar
- Chang HR, Pechere JC, Piguet PF (1992) Role of tumour necrosis factor in murine chronic toxoplasmic Toxoplasma gondii encephalitis. Immunol Infect Dis 2: 61–68.Google Scholar
- Freund YR, Slargato G, Jacob CO, Suzuki Y, Remington JS (1992) Polymorphisms in tumor necrosis factor α ( TNF- α) gene correlate with murine resistance to development of toxoplasmic encephalitis and with levels of TNF-a mRNA in infected brain tissue. J Exp Med 175: 683–688.PubMedCrossRefGoogle Scholar
- Ou-Yang K, Krug EC, Marr JJ, Berens RL (1990) Inhibition of growth of Toxoplasma gondii by qinghaosu and derivatives. Antimierob Agents Chemother 34: 1961–1965.Google Scholar
- Pfefferkorn ER (1978) Toxoplasma gondii: the enzymic defect of a mutant resistant to 5-fluorodeoxyuridine. Exp Parasitol 44:26–35.Google Scholar
- Summers WA (1949) The effects of oral administration of aureomycin, sulfathiazole, sulfamerazine, and 4,4-diaminodiphenylsulfone on toxoplasmosis in mice. Am er J Trop Med 29: 889–893.Google Scholar